Homepage - Well Referenced

Latest Articles

Association of Wearable Device-Measured Vigorous Intermittent Lifestyle Physical Activity with Mortality

This prospective cohort study analyzed data from 25,241 non-exercising adults (mean age 61.8 years) in the UK Biobank to assess the impact of vigorous intermittent lifestyle physical activity (VILPA) on mortality. VILPA, characterized by brief bouts (1–2 minutes) of vigorous activity during daily life, was measured using wearable accelerometers. Over

June 26, 2025 No Comments

Can a bout of exercise harm the human heart?

This commentary discusses a study by Stewart et al. (2016) that examined the effects of acute endurance exercise on cardiac function in recreationally active men. Participants performed two cycling trials: 90 minutes at heavy intensity and 120 minutes at moderate intensity. Findings indicated transient reductions in left and right ventricular

June 26, 2025 No Comments

Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine

This 2024 study evaluated the accuracy of a compact, disposable pressure monitoring device (Compass™) used during partial REBOA procedures in a swine model. Four Yorkshire pigs underwent induced hemorrhagic shock followed by REBOA with the Compass™ transducer. Mean arterial pressures recorded by the device were compared to standard arterial line

June 26, 2025 No Comments

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in

June 26, 2025 No Comments

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial

This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or

June 26, 2025 No Comments

Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database

This 2025 study conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) to identify drugs associated with noninfectious myocarditis. Analyzing data from 2004 to 2024, the researchers found 10,763 reports of noninfectious myocarditis. The top five drugs with the highest reporting odds ratios (RORs) were phendimetrazine tartrate

June 26, 2025 No Comments

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

This Phase II randomized, double-blind, placebo-controlled trial assessed the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (allo-hMSCs) in 30 elderly patients (mean age 75.5 years) with aging frailty. Participants received either 100 million or 200 million allo-hMSCs or placebo. No treatment-related serious adverse events were observed. The

Emerging Anti-Aging Strategies – Scientific Basis and Efficacy

This comprehensive review examines the scientific foundations and efficacy of emerging anti-aging strategies aimed at promoting healthier aging and mitigating age-related diseases. Key interventions discussed include caloric restriction, intermittent fasting, senolytics, sirtuin-activating compounds, NAD+ precursors, and stem cell therapies. The review highlights the mechanisms by which these strategies influence aging

Effect of Mesenchymal Stromal Cell Infusions on Lung Function in COPD Patients with High CRP Levels

This post-hoc analysis of a Phase 1/2 randomized, placebo-controlled trial evaluated the efficacy of systemic administration of bone marrow-derived allogeneic mesenchymal stromal cells (remestemcel-L) in COPD patients stratified by baseline C-reactive protein (CRP) levels. In patients with CRP ≥ 4 mg/L, remestemcel-L treatment led to significant improvements in forced expiratory

A Phase I Study for Intravenous Autologous Mesenchymal Stromal Cell Administration to Patients with Severe Emphysema

This Phase I open-label study evaluated the safety and feasibility of intravenous autologous bone marrow-derived mesenchymal stromal cell (MSC) administration in patients with severe emphysema undergoing lung volume reduction surgery (LVRS). Ten patients were enrolled; bone marrow was collected during the first LVRS to isolate and expand MSCs, followed by

Safety and Efficacy of Allogenic Placental Mesenchymal Stem Cells for Treating Knee Osteoarthritis: A Pilot Study

This double-blind, placebo-controlled pilot study evaluated the safety and efficacy of intra-articular injections of allogenic placental mesenchymal stem cells (MSCs) in 20 patients with symptomatic knee osteoarthritis (OA). Participants received either 0.5–0.6 × 10⁸ allogenic placenta-derived MSCs or saline placebo. Over 24 weeks, the MSC group demonstrated significant improvements in

Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial

This Phase I/II randomized controlled trial assessed the safety and efficacy of intra-articular injections of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in patients with symptomatic knee osteoarthritis (OA). Participants were randomized into three groups: hyaluronic acid (HA) injections at baseline and 6 months (n=8), a single UC-MSC dose at baseline

Intra-articular Injections of Expanded Mesenchymal Stem Cells with and without Addition of Platelet-Rich Plasma Are Safe and Effective for Knee Osteoarthritis

This randomized controlled trial evaluated the safety and efficacy of intra-articular injections of autologous expanded mesenchymal stem cells (MSCs) alone or combined with platelet-rich plasma (PRP) in 18 patients with symptomatic knee osteoarthritis (OA). Participants were randomized to receive either MSCs alone or MSCs plus PRP. Both groups demonstrated significant

A Phase I Clinical Trial of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells for Early-Stage Stargardt Macular Degeneration: 5-Years’ Follow-Up

This Phase I clinical trial evaluated the long-term safety and efficacy of subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells in seven patients with early-stage Stargardt macular degeneration (STGD1). Each patient received a single subretinal injection of 1 × 10⁵ hESC-RPE cells in one eye, with

Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium in Patients with Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy: Follow-Up of Two Open-Label Phase 1/2 Studies

This study reports on two open-label Phase 1/2 trials assessing the safety and tolerability of subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) in nine patients with atrophic age-related macular degeneration (AMD) and nine with Stargardt's macular dystrophy. Patients received varying doses (50,000 to 150,000 cells) and